Marker Therapeutics, Inc. (MRKR)
USD 1.05
(-4.55%)
USD 1.05
(-4.55%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -15.11 Million USD | -262.76% |
| 2022 | -4.16 Million USD | 86.33% |
| 2021 | -30.48 Million USD | -235.15% |
| 2020 | -9.09 Million USD | 79.05% |
| 2019 | -43.41 Million USD | 29.68% |
| 2018 | -61.74 Million USD | -1104.98% |
| 2017 | -5.12 Million USD | 34.69% |
| 2016 | -7.84 Million USD | -20.28% |
| 2015 | -6.52 Million USD | -7229.68% |
| 2014 | -89 Thousand USD | -102.59% |
| 2013 | 3.43 Million USD | 144.64% |
| 2012 | 1.4 Million USD | 64.04% |
| 2011 | 855.55 Thousand USD | -4.55% |
| 2010 | 896.29 Thousand USD | 355.92% |
| 2009 | 196.59 Thousand USD | -76.0% |
| 2008 | 818.97 Thousand USD | 69.45% |
| 2007 | 483.31 Thousand USD | 4.41% |
| 2006 | 462.9 Thousand USD | -4.83% |
| 2005 | 486.42 Thousand USD | 4.51% |
| 2004 | 465.45 Thousand USD | 2492.96% |
| 2003 | -19.45 Thousand USD | 96.97% |
| 2002 | -642.58 Thousand USD | -1170.98% |
| 2001 | 60 Thousand USD | 1153.39% |
| 2000 | 4787.00 USD | -95.64% |
| 1999 | 109.71 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -11.32 Million USD | 25.07% |
| 2024 Q2 | -7.8 Million USD | 31.11% |
| 2023 Q2 | -18.12 Million USD | -1766.41% |
| 2023 FY | -15.11 Million USD | -262.76% |
| 2023 Q1 | 1.08 Million USD | 126.11% |
| 2023 Q4 | -15.11 Million USD | 13.52% |
| 2023 Q3 | -17.47 Million USD | 3.58% |
| 2022 Q1 | -16.91 Million USD | 44.5% |
| 2022 Q2 | -14.26 Million USD | 15.69% |
| 2022 Q4 | -4.16 Million USD | 59.79% |
| 2022 FY | -4.16 Million USD | 86.33% |
| 2022 Q3 | -10.35 Million USD | 27.37% |
| 2021 Q4 | -30.48 Million USD | 16.92% |
| 2021 Q3 | -36.69 Million USD | 18.63% |
| 2021 FY | -30.48 Million USD | -235.15% |
| 2021 Q2 | -45.09 Million USD | 13.8% |
| 2021 Q1 | -52.31 Million USD | -475.19% |
| 2020 FY | -9.09 Million USD | 79.05% |
| 2020 Q1 | -39.81 Million USD | 8.29% |
| 2020 Q2 | -22.64 Million USD | 43.14% |
| 2020 Q3 | -14.72 Million USD | 34.95% |
| 2020 Q4 | -9.09 Million USD | 38.25% |
| 2019 Q2 | -52.86 Million USD | 7.39% |
| 2019 Q1 | -57.08 Million USD | 7.56% |
| 2019 FY | -43.41 Million USD | 29.68% |
| 2019 Q3 | -47.94 Million USD | 9.31% |
| 2019 Q4 | -43.41 Million USD | 9.44% |
| 2018 Q3 | -4.28 Million USD | 44.85% |
| 2018 Q4 | -61.74 Million USD | -1339.56% |
| 2018 Q1 | -2.79 Million USD | 45.43% |
| 2018 Q2 | -7.77 Million USD | -178.17% |
| 2018 FY | -61.74 Million USD | -1104.98% |
| 2017 Q4 | -5.12 Million USD | 32.6% |
| 2017 FY | -5.12 Million USD | 34.69% |
| 2017 Q3 | -7.6 Million USD | 23.65% |
| 2017 Q2 | -9.95 Million USD | -68.13% |
| 2017 Q1 | -5.92 Million USD | 24.52% |
| 2016 Q4 | -7.84 Million USD | 18.11% |
| 2016 Q3 | -9.58 Million USD | -156.22% |
| 2016 Q2 | -3.73 Million USD | 34.32% |
| 2016 Q1 | -5.69 Million USD | 12.72% |
| 2016 FY | -7.84 Million USD | -20.28% |
| 2015 Q3 | -6.03 Million USD | -97.68% |
| 2015 FY | -6.52 Million USD | -7229.68% |
| 2015 Q1 | -1.4 Million USD | -1473.63% |
| 2015 Q2 | -3.05 Million USD | -117.94% |
| 2015 Q4 | -6.52 Million USD | -8.11% |
| 2014 Q2 | 422.24 Thousand USD | -1.08% |
| 2014 Q3 | -560.7 Thousand USD | -232.79% |
| 2014 Q4 | -89 Thousand USD | 84.13% |
| 2014 FY | -89 Thousand USD | -102.59% |
| 2014 Q1 | 426.84 Thousand USD | -87.57% |
| 2013 Q1 | 2.03 Million USD | 45.19% |
| 2013 Q4 | 3.43 Million USD | 30.46% |
| 2013 FY | 3.43 Million USD | 144.64% |
| 2013 Q3 | 2.63 Million USD | 5.57% |
| 2013 Q2 | 2.49 Million USD | 22.34% |
| 2012 Q2 | 1.26 Million USD | 11.67% |
| 2012 Q4 | 1.4 Million USD | 1.96% |
| 2012 Q1 | 1.13 Million USD | 32.24% |
| 2012 Q3 | 1.37 Million USD | 8.95% |
| 2012 FY | 1.4 Million USD | 64.04% |
| 2011 FY | 855.55 Thousand USD | -4.55% |
| 2011 Q3 | 640.35 Thousand USD | 7.26% |
| 2011 Q2 | 596.98 Thousand USD | 29.14% |
| 2011 Q1 | 462.29 Thousand USD | -48.42% |
| 2011 Q4 | 855.55 Thousand USD | 33.61% |
| 2010 FY | 896.29 Thousand USD | 355.92% |
| 2010 Q1 | 463.63 Thousand USD | 135.84% |
| 2010 Q2 | -310.25 Thousand USD | -166.92% |
| 2010 Q3 | 225.99 Thousand USD | 172.84% |
| 2010 Q4 | 896.29 Thousand USD | 296.59% |
| 2009 Q1 | 1.04 Million USD | 27.06% |
| 2009 Q2 | 98.27 Thousand USD | -90.56% |
| 2009 Q3 | 127.75 Thousand USD | 30.0% |
| 2009 Q4 | 196.59 Thousand USD | 53.88% |
| 2009 FY | 196.59 Thousand USD | -76.0% |
| 2008 FY | 818.97 Thousand USD | 69.45% |
| 2008 Q2 | 1.11 Million USD | 22.38% |
| 2008 Q3 | 426.1 Thousand USD | -61.94% |
| 2008 Q4 | 818.97 Thousand USD | 92.2% |
| 2008 Q1 | 914.88 Thousand USD | 89.3% |
| 2007 Q2 | 55.44 Thousand USD | 251.91% |
| 2007 Q3 | 259.58 Thousand USD | 368.18% |
| 2007 Q1 | -36.49 Thousand USD | -107.88% |
| 2007 Q4 | 483.31 Thousand USD | 86.19% |
| 2007 FY | 483.31 Thousand USD | 4.41% |
| 2006 Q4 | 462.9 Thousand USD | 53.39% |
| 2006 Q2 | 1.01 Million USD | 85.95% |
| 2006 Q3 | 301.78 Thousand USD | -70.18% |
| 2006 Q1 | 544.21 Thousand USD | 11.88% |
| 2006 FY | 462.9 Thousand USD | -4.83% |
| 2005 FY | 486.42 Thousand USD | 4.51% |
| 2005 Q3 | 391.76 Thousand USD | 54.21% |
| 2005 Q4 | 486.42 Thousand USD | 24.16% |
| 2005 Q2 | 254.04 Thousand USD | 168.71% |
| 2005 Q1 | -369.74 Thousand USD | -179.44% |
| 2004 Q2 | 307.08 Thousand USD | 1829.29% |
| 2004 Q1 | -17.75 Thousand USD | 8.7% |
| 2004 FY | 465.45 Thousand USD | 2492.96% |
| 2004 Q4 | 465.45 Thousand USD | 6.75% |
| 2004 Q3 | 436.03 Thousand USD | 41.99% |
| 2003 Q3 | -83.25 Thousand USD | -80.19% |
| 2003 FY | -19.45 Thousand USD | 96.97% |
| 2003 Q1 | -375.37 Thousand USD | 41.58% |
| 2003 Q4 | -19.45 Thousand USD | 76.64% |
| 2003 Q2 | -46.2 Thousand USD | 87.69% |
| 2002 Q1 | -500.00 USD | -100.26% |
| 2002 Q2 | 70.44 Thousand USD | 14189.8% |
| 2002 Q3 | 10 Thousand USD | -85.81% |
| 2002 FY | -642.58 Thousand USD | -1170.98% |
| 2002 Q4 | -642.58 Thousand USD | -6525.89% |
| 2001 Q1 | 49.03 Thousand USD | -74.82% |
| 2001 FY | 60 Thousand USD | 1153.39% |
| 2001 Q4 | 189.99 Thousand USD | 678653.57% |
| 2001 Q3 | -28.00 USD | 93.05% |
| 2001 Q2 | -403.00 USD | -100.82% |
| 2000 Q4 | 194.78 Thousand USD | 56.73% |
| 2000 Q2 | 65.49 Thousand USD | -17.15% |
| 2000 Q3 | 124.28 Thousand USD | 89.76% |
| 2000 FY | 4787.00 USD | -95.64% |
| 2000 Q1 | 79.05 Thousand USD | 0.0% |
| 1999 FY | 109.71 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 72.986% |
| Alkermes plc | -166.73 Million USD | 90.937% |
| Agenus Inc. | 274.13 Million USD | 105.512% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 100.808% |
| Aptorum Group Limited | 1.35 Million USD | 1213.555% |
| Ardelyx, Inc. | 34.51 Million USD | 143.786% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | 453.071% |
| Bicycle Therapeutics plc | -481.46 Million USD | 96.861% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 141.787% |
| ChromaDex Corporation | -24.04 Million USD | 37.161% |
| Chimerix, Inc. | -25.51 Million USD | 40.779% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 316.867% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 36.177% |
| CRISPR Therapeutics AG | -150.84 Million USD | 89.982% |
| Precision BioSciences, Inc. | -85.41 Million USD | 82.307% |
| Dyadic International, Inc. | -6.37 Million USD | -136.927% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 5.156% |
| Fortress Biotech, Inc. | 7.66 Million USD | 297.149% |
| Lantern Pharma Inc. | -21.7 Million USD | 30.372% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 86.329% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | -76.883% |
| Incyte Corporation | -3.17 Billion USD | 99.524% |
| IO Biotech, Inc. | -140.69 Million USD | 89.26% |
| Jaguar Health, Inc. | 29.39 Million USD | 151.415% |
| Novavax, Inc. | -298.29 Million USD | 94.934% |
| Janux Therapeutics, Inc. | 5.33 Million USD | 383.145% |
| Opthea Limited | 28.15 Million USD | 153.668% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 9.992% |
| ContextLogic Inc. | -232 Million USD | 93.486% |
| MiMedx Group, Inc. | -33.9 Million USD | 55.425% |
| Pyxis Oncology, Inc. | 10.19 Million USD | 248.224% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | -552.191% |
| NextCure, Inc. | -6.47 Million USD | -133.309% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 70.077% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | -136.894% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | 224.238% |
| Vaxcyte, Inc. | -368.22 Million USD | 95.896% |
| PDS Biotechnology Corporation | -32.7 Million USD | 53.8% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | 187.461% |
| Pharming Group N.V. | 109.8 Million USD | 113.762% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 13.133% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 91.376% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 18.404% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 18.404% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -112.837% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | -157.875% |
| Acelyrin, Inc. | -216.9 Million USD | 93.033% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | -169.353% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | -776.534% |
| Summit Therapeutics Inc. | 34.67 Million USD | 143.582% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | -122.129% |
| Senti Biosciences, Inc. | 1.74 Million USD | 968.474% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 91.814% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 80.489% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | -149.282% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | 15246.438% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | 2506.282% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 87.089% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 91.018% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 113.63% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | -98.94% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 88.296% |
| Psyence Biomedical Ltd. | 6.89 Million USD | 319.178% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 93.765% |
| Immix Biopharma, Inc. | -17.5 Million USD | 13.697% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 95.229% |
| MEI Pharma, Inc. | -3.7 Million USD | -307.866% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | 220.785% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 109.343% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | 154.371% |
| Fortress Biotech, Inc. | 7.66 Million USD | 297.149% |
| Precigen, Inc. | -481 Thousand USD | -3041.674% |
| Clearside Biomedical, Inc. | 14.08 Million USD | 207.318% |
| AlloVir, Inc. | -62.69 Million USD | 75.896% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 72.828% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 124.505% |
| ImmuCell Corporation | 10.99 Million USD | 237.495% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 90.197% |
| Onconetix, Inc. | 5.33 Million USD | 383.44% |
| PureTech Health plc | -167.19 Million USD | 90.962% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 50.389% |
| Elevation Oncology, Inc. | -19.11 Million USD | 20.957% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | -207.832% |
| Seer, Inc. | -4.24 Million USD | -256.402% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 37.133% |
| Innoviva, Inc. | 255.56 Million USD | 105.913% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 72.95% |
| ESSA Pharma Inc. | -33.62 Million USD | 55.054% |
| GlycoMimetics, Inc. | -40.98 Million USD | 63.129% |
| GT Biopharma, Inc. | -1.02 Million USD | -1380.064% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 77.706% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 124.669% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 88.729% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | -9.061% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 47.661% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | -19959.269% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 51.035% |
| Aptose Biosciences Inc. | -8.19 Million USD | -84.402% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | -382.945% |
| Soligenix, Inc. | -4.95 Million USD | -205.183% |
| Century Therapeutics, Inc. | 847 Thousand USD | 1884.115% |
| Kura Oncology, Inc. | -20.11 Million USD | 24.886% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 63.076% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | -79.941% |
| Ocean Biomedical, Inc. | 1.82 Million USD | 929.527% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | -372.676% |
| Autolus Therapeutics plc | -186.59 Million USD | 91.902% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 69.35% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 94.521% |
| Eterna Therapeutics Inc. | 34.26 Million USD | 144.098% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 109.194% |
| GRI Bio, Inc. | -1.79 Million USD | -742.333% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | -68.222% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 54.562% |
| IGM Biosciences, Inc. | -72.6 Million USD | 79.187% |
| INmune Bio, Inc. | -25.41 Million USD | 40.532% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 110.011% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 70.17% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 7.003% |
| Entero Therapeutics, Inc. | -2.88 Million USD | -423.807% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 139.751% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 63.308% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 147.394% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 103.998% |
| Verastem, Inc. | -37.27 Million USD | 59.463% |
| Abeona Therapeutics Inc. | -9.07 Million USD | -66.554% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 70.862% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 0.156% |
| Histogen Inc. | -7.48 Million USD | -101.836% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 30.062% |
| Surrozen, Inc. | -32.66 Million USD | 53.737% |
| Organovo Holdings, Inc. | -1.5 Million USD | -902.75% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -259.498% |
| Ovid Therapeutics Inc. | 18.96 Million USD | 179.701% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 677.655% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | 463.606% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | -80.303% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 65.215% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | -3.667% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 95.23% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | -1992.825% |
| Apollomics, Inc. | -27.39 Million USD | 44.839% |
| Amarin Corporation plc | -191.04 Million USD | 92.09% |
| Mesoblast Limited | 55.96 Million USD | 127.003% |
| Turnstone Biologics Corp. | -14.58 Million USD | -3.617% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 40.252% |
| Synaptogenix, Inc. | -28.66 Million USD | 47.276% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | -1514.471% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 131.009% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -1652.887% |
| Monopar Therapeutics Inc. | -7.26 Million USD | -107.973% |
| Exelixis, Inc. | -73.05 Million USD | 79.314% |
| Better Therapeutics, Inc. | -860 Thousand USD | -1657.145% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 37.07% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 93.739% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 2153.002% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | -103.162% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 1305.06% |
| Gritstone bio, Inc. | 39.49 Million USD | 138.267% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 82.032% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | -474.113% |
| Avid Bioservices, Inc. | 169.72 Million USD | 108.903% |
| Insmed Incorporated | 721.62 Million USD | 102.094% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | -65.306% |
| MediWound Ltd. | -5.32 Million USD | -183.943% |
| OmniAb, Inc. | 9.2 Million USD | 264.201% |
| Alector, Inc. | -35.63 Million USD | 57.596% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 117.577% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | -206.645% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 214.143% |
| Zai Lab Limited | -775 Million USD | 98.05% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 104.437% |
| Aura Biosciences, Inc. | -21.52 Million USD | 29.796% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 81.679% |
| Immunic, Inc. | -45.34 Million USD | 66.671% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 92.179% |
| Veracyte, Inc. | -203.82 Million USD | 92.586% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 102.367% |
| FibroGen, Inc. | 56.76 Million USD | 126.62% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 269.696% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | -434.525% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | -629.899% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 100.329% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | -352.303% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 90.895% |
| TG Therapeutics, Inc. | 17.86 Million USD | 184.601% |
| Galecto, Inc. | -21.21 Million USD | 28.773% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 36.466% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 100.963% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 38.25% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | -31.324% |
| XBiotech Inc. | -200.02 Million USD | 92.445% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 82.032% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | 433.733% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 57.146% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 80.43% |
| Theravance Biopharma, Inc. | 5.69 Million USD | 365.532% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 91.133% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 83.641% |
| Vaxxinity, Inc. | 10.13 Million USD | 249.146% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 102.052% |
| Gain Therapeutics, Inc. | -10.76 Million USD | -40.342% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 77.089% |
| NexImmune, Inc. | -3.13 Million USD | -382.233% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | -337.674% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 44.238% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | -68.353% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | -12030.403% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 62.754% |
| Ainos, Inc. | 4.07 Million USD | 470.567% |
| Pluri Inc. | 22.82 Million USD | 166.194% |
| Prothena Corporation plc | -608.34 Million USD | 97.516% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 87.275% |
| Celularity Inc. | 65.19 Million USD | 123.181% |
| Rallybio Corporation | -24.1 Million USD | 37.302% |
| Cue Biopharma, Inc. | -33.81 Million USD | 55.317% |
| MeiraGTx Holdings plc | -40.3 Million USD | 62.504% |
| Omeros Corporation | 331.17 Million USD | 104.563% |
| Humacyte, Inc. | -22.48 Million USD | 32.796% |
| Immunocore Holdings plc | -358.59 Million USD | 95.786% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 38.509% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 51.097% |
| Blueprint Medicines Corporation | 702.83 Million USD | 102.15% |
| CalciMedica, Inc. | -5.53 Million USD | -173.263% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 91.971% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | -47.948% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 62.256% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 54.556% |
| Pulmatrix, Inc. | -10.41 Million USD | -45.065% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | -152.827% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 60.381% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 86.435% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 74.791% |
| Cytokinetics, Incorporated | 642.37 Million USD | 102.352% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | -159.513% |
| Nutriband Inc. | -251.65 Thousand USD | -5904.78% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 55.71% |
| Vor Biopharma Inc. | 4.3 Million USD | 451.429% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 99.75% |
| Evogene Ltd. | -19.63 Million USD | 23.034% |
| ProKidney Corp. | -56.23 Million USD | 73.129% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 68.952% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | -63.594% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 101.108% |
| CorMedix Inc. | -43.05 Million USD | 64.9% |
| BioLineRx Ltd. | 7.33 Million USD | 305.99% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 44.979% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 132.746% |
| Atai Life Sciences N.V. | -28.55 Million USD | 47.085% |
| Renovaro Biosciences Inc. | 2.23 Million USD | 777.483% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 33.768% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | 185.207% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 79.871% |
| MediciNova, Inc. | -50.78 Million USD | 70.243% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 80.824% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -67076.928% |
| GeoVax Labs, Inc. | -6.45 Million USD | -134.192% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 92.438% |
| Biomea Fusion, Inc. | -166.57 Million USD | 90.928% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 91.557% |
| Mereo BioPharma Group plc | -51.46 Million USD | 70.64% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 84.067% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 94.856% |
| Absci Corporation | -72.59 Million USD | 79.185% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 430.956% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 93.554% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 83.96% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 84.209% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 61.325% |
| Allakos Inc. | -24.97 Million USD | 39.494% |
| Imunon, Inc. | -4.21 Million USD | -258.614% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | -2.506% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 88.839% |
| BioAtla, Inc. | -109.01 Million USD | 86.138% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 2153.002% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | -1509.313% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | 226.287% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 28.73% |
| XOMA Corporation | -29 Million USD | 47.892% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 8.747% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -67.607% |
| aTyr Pharma, Inc. | -7.44 Million USD | -102.865% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 87.876% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 92.741% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 81.522% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 83.71% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | -1658.814% |
| Akari Therapeutics, Plc | -3.84 Million USD | -293.016% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 1031.144% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 101.094% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -1171.863% |
| UroGen Pharma Ltd. | 4.39 Million USD | 444.146% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 113.316% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | 21099.208% |
| Orgenesis Inc. | 21.78 Million USD | 169.369% |
| Entera Bio Ltd. | -10.62 Million USD | -42.172% |
| GH Research PLC | -78.07 Million USD | 80.645% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 32.199% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 43.316% |
| Xencor, Inc. | 29.64 Million USD | 150.976% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | -667.152% |
| Replimune Group, Inc. | 1.41 Million USD | 1170.216% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | -6070.256% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 88.046% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -1171.863% |
| Portage Biotech Inc. | -4.98 Million USD | -203.382% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -67076.928% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 77.146% |
| OncoCyte Corporation | -6.56 Million USD | -130.252% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | 1783.89% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | -231.708% |
| Purple Biotech Ltd. | -14.13 Million USD | -6.885% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 36.389% |
| scPharmaceuticals Inc. | -6.54 Million USD | -130.885% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 9.47% |
| HilleVax, Inc. | -165.48 Million USD | 90.868% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | -495.408% |
| Tharimmune, Inc. | -10.93 Million USD | -38.189% |
| Genprex, Inc. | -6.73 Million USD | -124.284% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 95.903% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 82.917% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | -978.619% |
| Virios Therapeutics, Inc. | -3.31 Million USD | -355.583% |
| OKYO Pharma Limited | -826.84 Thousand USD | -1727.597% |
| Savara Inc. | 153 Thousand USD | 9976.765% |
| Curis, Inc. | -23.88 Million USD | 36.738% |
| Daré Bioscience, Inc. | -5.15 Million USD | -192.976% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | -1847.322% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | -143.419% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | 1375.228% |
| BeiGene, Ltd. | -2.25 Billion USD | 99.329% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 222.474% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 97.515% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 91.857% |
| Erasca, Inc. | -37.21 Million USD | 59.395% |
| bluebird bio, Inc. | 108.57 Million USD | 113.918% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -1073.347% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 103.99% |
| DBV Technologies S.A. | -126.98 Million USD | 88.1% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -1073.347% |
| Moderna, Inc. | -2.9 Billion USD | 99.48% |
| Vincerx Pharma, Inc. | -10.35 Million USD | -45.976% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | -39.045% |
| Molecular Templates, Inc. | 707 Thousand USD | 2237.405% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 51.83% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 104.36% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 81.585% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 83.526% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 53.175% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 56.041% |
| MacroGenics, Inc. | -66.98 Million USD | 77.441% |
| RenovoRx, Inc. | -1.17 Million USD | -1188.274% |
| Adicet Bio, Inc. | -138.78 Million USD | 89.112% |
| Prime Medicine, Inc. | -27.94 Million USD | 45.917% |
| Aditxt, Inc. | 18.12 Million USD | 183.392% |
| Adagene Inc. | -87.62 Million USD | 82.755% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -262.783% |
| Quantum-Si incorporated | -118.55 Million USD | 87.254% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 141.97% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | -102.182% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 68.848% |
| SciSparc Ltd. | -2.06 Million USD | -631.789% |
| Vericel Corporation | 1.27 Million USD | 1283.356% |
| Revelation Biosciences, Inc. | -11.99 Million USD | -26.016% |
| Minerva Neurosciences, Inc. | 41 Million USD | 136.853% |
| Generation Bio Co. | 31.44 Million USD | 148.052% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 91.383% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 51.132% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 112.961% |
| Invivyd, Inc. | -198.47 Million USD | 92.386% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 83.26% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | -530.251% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 78.653% |
| Artelo Biosciences, Inc. | -6.82 Million USD | -121.413% |
| 2seventy bio, Inc. | 181.71 Million USD | 108.316% |
| ADMA Biologics, Inc. | 90.06 Million USD | 116.778% |
| Clene Inc. | 3.34 Million USD | 552.439% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | -66.376% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 29.75% |
| GeoVax Labs, Inc. | -6.45 Million USD | -134.192% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 95.609% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 41.878% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 108.506% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | -269.332% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 402.108% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | -190.103% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 88.403% |
| Evaxion Biotech A/S | 5.28 Million USD | 385.831% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 86.576% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 88.489% |
| Trevena, Inc. | 2.25 Million USD | 769.24% |
| Surrozen, Inc. | -32.66 Million USD | 53.737% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 70.663% |
| Cingulate Inc. | 3.08 Million USD | 590.204% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | -414.52% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 310.261% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | -62.642% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 80.949% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 88.504% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 85.682% |
| Clearmind Medicine Inc. | -3.94 Million USD | -283.283% |
| Kronos Bio, Inc. | -36.05 Million USD | 58.087% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | 260.606% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 1136.36% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 72.148% |
| Statera Biopharma, Inc. | 14.41 Million USD | 204.821% |
| ImmunityBio, Inc. | 618.22 Million USD | 102.444% |
| Korro Bio, Inc. | -132.94 Million USD | 88.633% |
| Kineta, Inc. | -4.54 Million USD | -232.778% |
| BioVie Inc. | -17.73 Million USD | 14.78% |
| Codexis, Inc. | -43.27 Million USD | 65.077% |
| Celularity Inc. | 65.19 Million USD | 123.181% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | -376.852% |
| Celcuity Inc. | 6.78 Million USD | 322.767% |
| Virax Biolabs Group Limited | -3.36 Million USD | -349.085% |
| Cibus, Inc. | -8.07 Million USD | -87.069% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | -257.329% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 430.666% |
| IN8bio, Inc. | -16.38 Million USD | 7.795% |
| Kodiak Sciences Inc. | -103.87 Million USD | 85.452% |
| Annexon, Inc. | -193.75 Million USD | 92.201% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | 42076.25% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 13.644% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | -330.158% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 101.433% |
| Eyenovia, Inc. | 1.25 Million USD | 1300.558% |
| Puma Biotechnology, Inc. | 26.9 Million USD | 156.166% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -365.971% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 54.548% |
| Arcellx, Inc. | -296.95 Million USD | 94.911% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 22.529% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 74.333% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 27.093% |
| Moolec Science SA | 117.61 Thousand USD | 12948.124% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 60.646% |
| Geron Corporation | 14.76 Million USD | 202.374% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 60.147% |
| Royalty Pharma plc | 5.65 Billion USD | 100.267% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 89.315% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | -116.205% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | -181.78% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 89.262% |
| Humacyte, Inc. | -22.48 Million USD | 32.796% |
| Structure Therapeutics Inc. | -124.33 Million USD | 87.847% |
| 89bio, Inc. | -289.05 Million USD | 94.772% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 40.134% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | -747.529% |
| Genelux Corporation | -6.89 Million USD | -119.038% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 51.346% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 118.076% |
| Notable Labs, Ltd. | -9.77 Million USD | -54.577% |
| Liquidia Corporation | -80.17 Million USD | 81.152% |
| Mustang Bio, Inc. | -3.73 Million USD | -304.482% |
| Immunovant, Inc. | -635.22 Million USD | 97.621% |
| Quantum-Si incorporated | -118.55 Million USD | 87.254% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 13.964% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | -264.747% |
| Vera Therapeutics, Inc. | 8.02 Million USD | 288.258% |
| Acasti Pharma Inc. | -23 Million USD | 34.312% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | -348.78% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 7.003% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 89.029% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | -384.907% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 32.028% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 18.62% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 91.073% |
| PepGen Inc. | -60.67 Million USD | 75.092% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 34.229% |
| United Therapeutics Corporation | -507.7 Million USD | 97.024% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 20.99% |
| Solid Biosciences Inc. | -47.75 Million USD | 68.353% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -1652.887% |
| Immuneering Corporation | -54.94 Million USD | 72.496% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -259.498% |
| Silo Pharma, Inc. | -3.52 Million USD | -328.778% |
| Belite Bio, Inc | -87.27 Million USD | 82.684% |
| XOMA Corporation | -29 Million USD | 47.892% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 78.625% |
| Bionomics Limited | 227 Million USD | 106.657% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 87.004% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -496.583% |
| uniQure N.V. | -102.95 Million USD | 85.322% |
| Cassava Sciences, Inc. | -121.13 Million USD | 87.525% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -262.783% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 136.901% |
| Forte Biosciences, Inc. | -11.96 Million USD | -26.339% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | -388.38% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | 14356.085% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -365.971% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 269.696% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | -103.768% |
| Altimmune, Inc. | -134.48 Million USD | 88.764% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 107.63% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -496.583% |
| Compugen Ltd. | -12.9 Million USD | -17.107% |
| Peak Bio, Inc. | 10.34 Million USD | 246.143% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | -5239.735% |
| Benitec Biopharma Inc. | -50.58 Million USD | 70.125% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 85.517% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | 176.923% |
| Zura Bio Limited | -99.8 Million USD | 84.859% |
| PolyPid Ltd. | 6.17 Million USD | 344.918% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 120.388% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | 176.923% |
| Instil Bio, Inc. | 75.35 Million USD | 120.053% |
| argenx SE | -2.02 Billion USD | 99.255% |
| Immunome, Inc. | -97.02 Million USD | 84.426% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 32.823% |
| Verona Pharma plc | -220.44 Million USD | 93.145% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 78.937% |
| Shattuck Labs, Inc. | -121.42 Million USD | 87.555% |
| CervoMed Inc. | -7.79 Million USD | -93.914% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 91.854% |
| Plus Therapeutics, Inc. | -4.37 Million USD | -245.563% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 88.529% |
| Moolec Science SA | 117.61 Thousand USD | 12948.124% |
| Enveric Biosciences, Inc. | -2.28 Million USD | -560.472% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | 195.05% |
| AnaptysBio, Inc. | -18.15 Million USD | 16.746% |
| Design Therapeutics, Inc. | -18.15 Million USD | 16.741% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 78.529% |
| NeurAxis, Inc. | 145.7 Thousand USD | 10471.62% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | 234.539% |
| Lumos Pharma, Inc. | -28.49 Million USD | 46.964% |
| Achilles Therapeutics plc | -126.92 Million USD | 88.094% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 78.937% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | -2204.523% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 27.257% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 1136.36% |
| Nutriband Inc. | -251.65 Thousand USD | -5904.78% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | -14.733% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | -103.111% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 104.442% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | 163.667% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 96.623% |
| Palisade Bio, Inc. | -12.06 Million USD | -25.271% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 89.23% |
| Beam Therapeutics Inc. | -262.72 Million USD | 94.248% |
| Neurogene Inc. | -131.95 Million USD | 88.548% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | 169.268% |
| AEON Biopharma, Inc. | -4.88 Million USD | -209.661% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 95.994% |
| Sesen Bio, Inc. | -112.55 Million USD | 86.574% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 84.867% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | -543.645% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 61.279% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 81.855% |
| Athira Pharma, Inc. | -88.99 Million USD | 83.021% |
| Vaccinex, Inc. | -1.28 Million USD | -1073.249% |
| HCW Biologics Inc. | 2.85 Million USD | 628.987% |
| XOMA Corporation | -29 Million USD | 47.892% |
| Nektar Therapeutics | 210.24 Million USD | 107.188% |
| Arvinas, Inc. | -313.8 Million USD | 95.184% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 1031.144% |
| Merus N.V. | -192.88 Million USD | 92.166% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 125.192% |
| Quince Therapeutics, Inc. | -6.93 Million USD | -117.807% |
| Rezolute, Inc. | -68.16 Million USD | 77.832% |
| Clene Inc. | 3.34 Million USD | 552.439% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | -14.594% |
| BeyondSpring Inc. | -13.75 Million USD | -9.862% |
| Synlogic, Inc. | -6.68 Million USD | -126.05% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | 1432.579% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | -78.728% |
| Peak Bio, Inc. | 10.34 Million USD | 246.143% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 81.665% |
| Krystal Biotech, Inc. | -350.23 Million USD | 95.685% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 112.174% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 91.058% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | -378.643% |
| MannKind Corporation | 143.89 Million USD | 110.501% |
| Ikena Oncology, Inc. | -109.15 Million USD | 86.156% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | -99.596% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 54.346% |
| Gossamer Bio, Inc. | 180.35 Million USD | 108.379% |
| CohBar, Inc. | -5.93 Million USD | -154.799% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 49.202% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 430.956% |
| Legend Biotech Corporation | -949.39 Million USD | 98.408% |
| Mural Oncology plc | -255.84 Million USD | 94.093% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 146.908% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | -220.794% |
| Disc Medicine, Inc. | -358.28 Million USD | 95.782% |
| Champions Oncology, Inc. | 4.81 Million USD | 414.037% |
| REGENXBIO Inc. | 54.76 Million USD | 127.592% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | -5519.582% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 89.994% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | -67.681% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 81.271% |
| Vaxart, Inc. | -8.24 Million USD | -83.369% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 69.885% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 88.117% |
| Cellectis S.A. | -43.85 Million USD | 65.542% |
| Longeveron Inc. | -2.9 Million USD | -419.651% |
| Repare Therapeutics Inc. | -107.85 Million USD | 85.989% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 101.56% |
| Inozyme Pharma, Inc. | 12 Million USD | 225.887% |
| Revolution Medicines, Inc. | -608.2 Million USD | 97.515% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | -1128.573% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 94.3% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 89.931% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 3.423% |
| Anixa Biosciences, Inc. | -740 Thousand USD | -1942.088% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.842% |
| Denali Therapeutics Inc. | -74.86 Million USD | 79.815% |
| Revelation Biosciences, Inc. | -11.99 Million USD | -26.016% |
| Veru Inc. | 4.77 Million USD | 416.141% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | -34.372% |
| Cingulate Inc. | 3.08 Million USD | 590.204% |
| Passage Bio, Inc. | 4.58 Million USD | 429.585% |
| Context Therapeutics Inc. | -14.44 Million USD | -4.579% |
| Exicure, Inc. | 5.84 Million USD | 358.36% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 93.441% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 61.811% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | 196.306% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 74.309% |
| Nuvalent, Inc. | -335.38 Million USD | 95.494% |
| ABVC BioPharma, Inc. | 1.73 Million USD | 971.308% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 79.711% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | -69.983% |
| OmniAb, Inc. | 9.2 Million USD | 264.201% |
| Anew Medical, Inc. | 1.43 Million USD | 1154.926% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | 192.246% |
| Lipocine Inc. | -4.75 Million USD | -217.829% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 86.241% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | 199.215% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 70.17% |
| G1 Therapeutics, Inc. | 24.89 Million USD | 160.708% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | -124.839% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 77.044% |
| Ocugen, Inc. | -32.52 Million USD | 53.533% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 82.341% |
| Q32 Bio Inc. | -37.94 Million USD | 60.179% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | -2306.282% |
| Alumis Inc. Common Stock | -13.52 Million USD | -11.697% |
| Equillium, Inc. | -22.39 Million USD | 32.514% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 40.897% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 53.684% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | -5995.416% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 111.274% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 572.528% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 4700.963% |
| Dominari Holdings Inc. | 195 Thousand USD | 7849.462% |
| Edesa Biotech, Inc. | -5.26 Million USD | -186.913% |
| vTv Therapeutics Inc. | -8.91 Million USD | -69.468% |
| Bio-Techne Corporation | 267.74 Million USD | 105.644% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 6.771% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 87.204% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | -79.834% |
| Candel Therapeutics, Inc. | -12.65 Million USD | -19.449% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 93.835% |
| Nkarta, Inc. | 57.29 Million USD | 126.373% |
| BioCardia, Inc. | 212 Thousand USD | 7228.042% |
| Iterum Therapeutics plc | 13.43 Million USD | 212.453% |